Nestlé has acquired the full rights to commercialise several key aesthetic dermatology products from Canadian firm Valeant Pharmaceuticals International. The $1.4bn acquisition will give Nestlé commercialisation rights in the US and Canada for Valeant’s Restylane, Perlane and Emervel products, used for corrective facial aesthetic treatments, and for Dysport, an aesthetic dermatology treatment. It will also give the global giant rights to Sculptra, an injectable poly-L-lactic acid treatment.
The acquisition follows the creation earlier this year of Nestlé Skin Health. Nestlé Chief Executive Paul Bulcke said: “This move will reinforce Galderma’s leading position in the industry when it becomes Nestlé Skin Health by allowing it to complete its geographic footprint for its strong portfolio of brands and leading medical solutions globally.”
Nestlé expects to complete its acquisition of Galderma in July and would expect to operate the acquired assets through Galderma. J Michael Pearson, Chairman and CEO of Valeant said: “Galderma, under the leadership of Humberto Antunes, CEO of Galderma, not only has a history of building strong businesses, but is firmly committed to the aesthetic dermatology.”
